Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9HCE0
UPID:
EPG5_HUMAN
Alternative names:
-
Alternative UPACC:
Q9HCE0; A2BDF3; Q9H8C8
Background:
Ectopic P granules protein 5 homolog plays a crucial role in autophagy, facilitating the clearance of autophagosomal cargo. It is pivotal in the immune response to pathogens by mediating the translocation of CpG dinucleotides, essential for activating the TLR9 receptor in late endosomes and lysosomes.
Therapeutic significance:
This protein's involvement in Vici syndrome, a condition marked by a spectrum of severe physical and neurological abnormalities, underscores its potential as a target for therapeutic intervention. Understanding the role of Ectopic P granules protein 5 homolog could open doors to potential therapeutic strategies.